GlobeNewsWire
18 Jun 2026, 20:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Teva has submitted an NDA for Ecopipam following positive Phase 3 data published in JAMA Neurology. — The transition from Phase 3 to NDA submission for a first-in-class drug is a major catalyst for potential revenue growth and valuation.
+0.60Teva will release its second quarter 2026 financial results on July 29, 2026. — Scheduled earnings dates are routine administrative events with low immediate market impact until the actual data is released.
+0.10Which stocks this story touches
The company announced positive Phase 3 data for Ecopipam and is preparing to report Q2 financial results.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
